New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2011
08:27 EDTPIP, SIGAPharmAthene, SIGA Technologies should merge, says Roth Capital
Roth Capital believes that the best course of action for PharmAthene(PIP) and SIGA (SIGA) would be to merge, although the firm adds that this isn't necessarily the most likely scenario. The firm thinks that both companies would benefit from a merger and it maintains a $6.25 target and Buy rating on PharmAthene.
News For PIP;SIGA From The Last 14 Days
Check below for free stories on PIP;SIGA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 11, 2014
09:06 EDTPIP, SIGAOn The Fly: Pre-market Movers
HIGHER: PharmAthene (PIP), up 55% after announcing that a Delaware court awarded the company lump sum expectation damages for the value of its lost profits for SIGA Technologies' (SIGA) smallpox antiviral, Tecovirimat... MannKind (MNKD), up 19% after entering exclusive licensing agreement for development and commercialization of Afrezza inhaled insulin with Sanofi (SNY)... Kinder Morgan (KMI), up 19% after announcing it will acquire all of the outstanding equity securities of Kinder Morgan Energy Partners (KMP), Kinder Morgan Management (KMR) and El Paso Pipeline Partners (EPB)... Tesla (TSLA), up 2.7% following upgrade at Deutsche Bank... Achillion (ACHN), up 6% following upgrades at Wells Fargo and at Piper Jaffray... PepsiCo (PEP), up 0.9% following upgrade at UBS. LOWER: Dean Foods (DF), down 8.6% after reporting Q2 losses that were steeper than expected, saying balance of year "appears rocky," which makes it difficult to provide guidance beyond the immediate quarter... Priceline (PCLN), down 0.7% after reporting Q2 revenue that missed expectations, guiding Q3 EPS below consensus... SIGA Technologies, down 31% after ruling in suit with PharmAthene... 2U (TWOU), down 4.3% after downgraded at Goldman.
08:56 EDTPIPPharmAthene price target raised to $6 from $4 at Aegis
Subscribe for More Information
August 10, 2014
14:23 EDTPIP, SIGAPharmAthene awarded lump sum expectation damages from SIGA Technologies
PharmAthene (PIP) announced that on August 8, the Delaware Court of Chancery issued a Memorandum Opinion and awarded to PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA Technologies (SIGA) smallpox antiviral, Tecovirimat. In addition, the Court ordered SIGA to pay prejudgment interest and varying percentages of PharmAthene's reasonable attorneys' and expert witness fees."We are extremely pleased by the Chancery Court's ruling to award PharmAthene lump sum expectancy damages that it suffered due to SIGA's breach of contract," said Eric I. Richman, President and CEO. "We look forward to working with our damages expert to calculate the lump sum damage amounts in accordance with the Court's decision and its instructions in the accompanying order."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use